» Articles » PMID: 37816758

Proteomics of CKD Progression in the Chronic Renal Insufficiency Cohort

Abstract

Progression of chronic kidney disease (CKD) portends myriad complications, including kidney failure. In this study, we analyze associations of 4638 plasma proteins among 3235 participants of the Chronic Renal Insufficiency Cohort Study with the primary outcome of 50% decline in estimated glomerular filtration rate or kidney failure over 10 years. We validate key findings in the Atherosclerosis Risk in the Communities study. We identify 100 circulating proteins that are associated with the primary outcome after multivariable adjustment, using a Bonferroni statistical threshold of significance. Individual protein associations and biological pathway analyses highlight the roles of bone morphogenetic proteins, ephrin signaling, and prothrombin activation. A 65-protein risk model for the primary outcome has excellent discrimination (C-statistic[95%CI] 0.862 [0.835, 0.889]), and 14/65 proteins are druggable targets. Potentially causal associations for five proteins, to our knowledge not previously reported, are supported by Mendelian randomization: EGFL9, LRP-11, MXRA7, IL-1 sRII and ILT-2. Modifiable protein risk markers can guide therapeutic drug development aimed at slowing CKD progression.

Citing Articles

A multi-modal fusion model with enhanced feature representation for chronic kidney disease progression prediction.

Qiao Y, Zhou H, Liu Y, Chen R, Zhang X, Nie S Brief Bioinform. 2025; 26(1).

PMID: 39913621 PMC: 11801269. DOI: 10.1093/bib/bbaf003.


Proteomics analysis reveals age-related proteins in the urine of chronic kidney disease patients.

Xiong L, Wu C, Chen S, Zhang Y, Wang L, Li Y Front Med (Lausanne). 2025; 11():1506134.

PMID: 39835101 PMC: 11743183. DOI: 10.3389/fmed.2024.1506134.


The significance of matrix remodeling associated 7 (MXRA7) in pathogenesis or management of renal diseases deserves more investigations.

Wang Y Ren Fail. 2025; 47(1):2449575.

PMID: 39780515 PMC: 11721947. DOI: 10.1080/0886022X.2024.2449575.


Proteomics and Incident Kidney Failure in Individuals With CKD: The African American Study of Kidney Disease and Hypertension and the Boston Kidney Biopsy Cohort.

Chen T, Surapaneni A, Schmidt I, Waikar S, Coresh J, Liu H Kidney Med. 2024; 6(12):100921.

PMID: 39634331 PMC: 11615895. DOI: 10.1016/j.xkme.2024.100921.


Classification of Predictors of Rapid Development of Kidney Failure and Short-Term Changes in Concentration of Circulating Proteins.

Kobayashi H, Looker H, Ihara K, Md Dom Z, Satake E, Tye S Clin J Am Soc Nephrol. 2024; .

PMID: 39480511 PMC: 11835163. DOI: 10.2215/CJN.0000000603.


References
1.
Parsa A, Kanetsky P, Xiao R, Gupta J, Mitra N, Limou S . Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study. J Am Soc Nephrol. 2016; 28(3):923-934. PMC: 5328149. DOI: 10.1681/ASN.2015101152. View

2.
Lindquist J, Mertens P . Myofibroblasts, regeneration or renal fibrosis--is there a decisive hint?. Nephrol Dial Transplant. 2013; 28(11):2678-81. DOI: 10.1093/ndt/gft247. View

3.
Williams S, Ostroff R, Hinterberg M, Coresh J, Ballantyne C, Matsushita K . A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Sci Transl Med. 2022; 14(639):eabj9625. DOI: 10.1126/scitranslmed.abj9625. View

4.
Suresh S, de Castro L, Dey S, Robey P, Noguchi C . Erythropoietin modulates bone marrow stromal cell differentiation. Bone Res. 2019; 7:21. PMC: 6804931. DOI: 10.1038/s41413-019-0060-0. View

5.
Golestaneh L, Alvarez P, Reaven N, Funk S, McGaughey K, Romero A . All-cause costs increase exponentially with increased chronic kidney disease stage. Am J Manag Care. 2017; 23(10 Suppl):S163-S172. View